The start-up Allogenica is developing innovative biotherapies for blood cancers.

Founded in January 2022, Allogenica specialized in the development of universal Chimeric Antigen Receptor T-cell-therapies (CAR-T cells-therapies) to treat certain forms of blood cancers such as leukemias and lymphomas. The biotech company has just completed its first round of fundraising, raising €500,000 to advance the development of its bioproduction platform.

Led by Inna Menkova and supported by PULSALYS, Allogenica aims to offer a of-the-shelf, cost-effective, and safer treatments to address a larger number of patients affected by blood cancers.

Download Press Release (in French)